Work

Upadacitinib Monotherapy for Treatment of Pyoderma Gangrenosum

Year: 2025

Type: article

Abstract: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis that results in progressive, painful ulcers most commonly affecting the lower extremities. Although immunosuppressants are frequently used for therapy, there is no standard treatment approach, and recurrences are common. The pathogenesis of PG is believed to involve dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, supporting the potential use of JAK/STAT inhibitors as a treatment option. This case series describes the successful use of upadacitinib, a selective JAK inhibitor, in the management of PG.

Source: American Journal of Medicine Open

DOI: 10.1016/j.ajmo.2025.100112

Authors: Mohamad R. Taha, Harrison P. Nguyen, Stephen K. Tyring

Institutions: Texas A&M Health Science Center, Texas A&M University, Center for Clinical Studies, The University of Texas Health Science Center at Houston

Language: English

Topic: Autoimmune and Inflammatory Disorders

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,540